学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

森本真司（モリモトシンジ）

研究テーマ	膠原病、特に全身性エリテマトーデスの病態における免疫機構の解析
研究業績（論文）	１なし、２なし、３なし、４なし、５なし、６．論文 1. Hayakawa K, Fujishiro M, Yoshida Y, Kataoka Y, Sakuma S, Nishi T, Ikeda K, Morimoto S, Takamori K, Sekigawa I. Exposure of female NZBWF1 mice to imiquimod-induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset. Clin Exp Immunol. 2022 13;208(1):33-46. 2. Suzuki S, Ikeda K, Yamaji K, Tamura N, Morimoto. S. Recurrence in long-term survivor of antiMDA5 antibody-positive clinically amyopathic dermatomyositis: case series and literature review. Mod Rheum Case Rep. DOI: 10.1080/24725625.2021.1886666. 2021 3. Kogami M, Suzuki S, Nanjo Y, Ikeda K, Tamura N, Sasaki S, Morimoto S. Complication of COVID-19 during remission induction therapy against anti-MDA-5 antibody positive dermatomyositis. Rheumatology Ad Prac. https://doi.org/10.1093/rap/rkaa068. 2020 4. Yoshida Y, Hayakawa K, Fujishiro M, Ikeda K, Tsushima H, Hirai T, Kawasaki M, Tominaga M, Suga Y, Takamori K, Watanabe Y, Sekigawa I, Morimoto S. Social defeat stress exacerbates atopic dermatitis through downregulation of DNA methyltransferase 1 and upregulation of C-C motif chemokine receptor 7 in skin dendritic cells. Biochem Biophys Res Commun. 529: 1073-1079. 2020 5. Matsuoka Y, Morimoto S, Fujishiro M, Hayakawa K, Kataoka Y, Suzuki S, Ikeda K, Takamori K, Yamaji K, Tamura N. Metoformin repositioning in rheumatoid arthritis. Clin Exp Rheumatol. in press. 2020 6. Suzuki S, Ogiwara K, Nishi T, Sakuma S, Akira M, Iwasaki M, Honda D, Takahara H, Ikeda K, Yamaji K, Tamura N, Rinno H, Morimoto S. A case of MPO-ANCA positive systemic lupus erythematosus developed into acute kidney injury. Arch Clin Med Case Rep. 3: 560-566. 2019 7. Hayakawa K, Kawasaki M, Hirai T, Yoshida Y, Tsushima H, Fujishiro M, Ikeda K, Morimoto S, Takamori K, Sekigawa I. MicroRNA-766-3p Contributes to Anti-Inflammatory responses through the indirect inhibition of NF-kappaB signaling. Int J Mol Sci. 20: 809-823. 2019 8. Ikeda K, Sekiguchi N, Hirai T, Tanji K, Zushi A, Inoue M, Takasago M, Komatsu T, Morimoto S, Yamaji K, Takamori K, Tamura N, Sekigawa I. Securely collecting multidimensional health information from patients with rheumatoid arthritis using smart device technology: Beneficial effect for physicians and patients. Musculoskeletal Care. 16:494-9.2018 9. Niimi N, Miyashita T, Tanji K, Hirai T, Watanabe K, Ikeda K, Morimoto S, Sekigawa I. Aortic Aneurysm as a Complication of Granulomatosis with Polyangiitis Successfully Treated with Prednisolone and Cyclophosphamide: A Case Report and Review of the Literature. Case Rep Rheumatol. :9682801.2018 10. Hayakawa K, Ikeda K, Fujishiro M, Yoshida Y, Hirai T, Tsushima H, Miyashita T, Morimoto S, Suga Y, Takamori K, Ogawa H, Sekigawa I. Connective Tissue Growth Factor Neutralization Aggravates the Psoriasis Skin Lesion: The Analysis of Psoriasis Model Mice and Patients. Ann Dermatol.;30:47-53. 2018 11. Hirai T, Ikeda K, Tsushima H, Fujishiro M, Hayakawa K, Yoshida Y, Morimoto S, Yamaji K, Takasaki Y, Takamori K, Tamura N, Sekigawa I. Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. Inflamm Regen.;38:1-9. 2018 12. Tsushima H, Morimoto S, Fujishiro M, Yoshida Y, Hayakawa K, Hirai T, Miyashita T, Ikeda K, Yamaji K, Takamori K, Takasaki Y, Sekigawa I, Tamura N. Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis. Autoimmunity.;50:329-335. 2017 13. Sugiura-Ogasawara M, Omae Y, Kawashima M, Toyo-Oka L, Khor SS, Sawai H, Horita T, Atsumi T, Murashima A, Fujita D, Fujita T, Morimoto S, Morishita E, Katsuragi S, Kitaori T, Katano K, Ozaki Y, Tokunaga K. The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome. J Hum Genet.;62:831-838. 2017 14. Miyashita T, Morimoto S, Honda D, Nakano S, Amano H, Osawa I, Yamaji K, Tomino Y, Takasaki Y, Tamura N. Outcomes of the Re-classification of WHO Class IV Lupus Nephritis Using the ISN/RPS Classification: a Single Center Retrospective Observational Study from the JUDE Study. Juntendo Medical Journal.;63:362-369. 2017 15. Minowa K, Amano H, Ando S, Watanabe T, Ogasawara M, Kawano S, Kaneko T, Morimoto S, Yamaji K, Tamura N, Tokano Y, Hashimoto H, Takasaki Y. Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study. Mod Rheumatol.;27:72-76. 2017 16. Ikeda K, Watanabe K, Hirai T, Tanji K, Miyashita T, Nakajima S, Uomori K, Morimoto S, Takamori K, Ogawa H, Takasaki Y, Sekigawa I. Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies. Intern Med.;56:1147-1152. 2017 17. Ikeda K, Nakajima S, Tanji K, Hirai T, Uomori K, Morimoto S, Tomita S, Fukunaga M, Tamura N, Sekigawa I. Intestinal perforation due to hemorrhagic Cytomegalovirus enteritis in a patient with severe uncontrolled lupus nephritis: a case and review of the literature. Rheumatol Int. ;37:1395-1399. 2017 18. Ikeda K, Hayakawa K, Fujishiro M, Kawasaki M, Hirai T, Tsushima H, Miyashita T, Suzuki S, Morimoto S, Tamura N, Takamori K, Ogawa H, Sekigawa I. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol.;18:41. 2017 19. Hirai T, Ikeda K, Fujishiro M, Tsushima H, Hayakawa K, Suzuki S, Yamaguchi A, Nozawa K, Morimoto S, Takasaki Y, Ogawa H, Takamori K, Tamura N, Sekigawa I. The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study. Clin Rheumatol.; 36:51-8. 2017

研究テーマ

膠原病、特に全身性エリテマトーデスの病態における免疫機構の解析

研究業績（論文）

１なし、２なし、３なし、４なし、５なし、
６．論文
1. Hayakawa K, Fujishiro M, Yoshida Y, Kataoka Y, Sakuma S, Nishi T, Ikeda K, Morimoto S, Takamori K, Sekigawa I. Exposure of female NZBWF1 mice to imiquimod-induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset. Clin Exp Immunol. 2022 13;208(1):33-46.
2. Suzuki S, Ikeda K, Yamaji K, Tamura N, Morimoto. S. Recurrence in long-term survivor of antiMDA5 antibody-positive clinically amyopathic dermatomyositis: case series and literature review. Mod Rheum Case Rep. DOI: 10.1080/24725625.2021.1886666. 2021
3. Kogami M, Suzuki S, Nanjo Y, Ikeda K, Tamura N, Sasaki S, Morimoto S. Complication of COVID-19 during remission induction therapy against anti-MDA-5 antibody positive dermatomyositis. Rheumatology Ad Prac. https://doi.org/10.1093/rap/rkaa068. 2020
4. Yoshida Y, Hayakawa K, Fujishiro M, Ikeda K, Tsushima H, Hirai T, Kawasaki M, Tominaga M, Suga Y, Takamori K, Watanabe Y, Sekigawa I, Morimoto S. Social defeat stress exacerbates atopic dermatitis through downregulation of DNA methyltransferase 1 and upregulation of C-C motif chemokine receptor 7 in skin dendritic cells. Biochem Biophys Res Commun. 529: 1073-1079. 2020
5. Matsuoka Y, Morimoto S, Fujishiro M, Hayakawa K, Kataoka Y, Suzuki S, Ikeda K, Takamori K, Yamaji K, Tamura N. Metoformin repositioning in rheumatoid arthritis. Clin Exp Rheumatol. in press. 2020
6. Suzuki S, Ogiwara K, Nishi T, Sakuma S, Akira M, Iwasaki M, Honda D, Takahara H, Ikeda K, Yamaji K, Tamura N, Rinno H, Morimoto S. A case of MPO-ANCA positive systemic lupus erythematosus developed into acute kidney injury. Arch Clin Med Case Rep. 3: 560-566. 2019
7. Hayakawa K, Kawasaki M, Hirai T, Yoshida Y, Tsushima H, Fujishiro M, Ikeda K, Morimoto S, Takamori K, Sekigawa I. MicroRNA-766-3p Contributes to Anti-Inflammatory responses through the indirect inhibition of NF-kappaB signaling. Int J Mol Sci. 20: 809-823. 2019
8. Ikeda K, Sekiguchi N, Hirai T, Tanji K, Zushi A, Inoue M, Takasago M, Komatsu T, Morimoto S, Yamaji K, Takamori K, Tamura N, Sekigawa I. Securely collecting multidimensional health information from patients with rheumatoid arthritis using smart device technology: Beneficial effect for physicians and patients. Musculoskeletal Care. 16:494-9.2018
9. Niimi N, Miyashita T, Tanji K, Hirai T, Watanabe K, Ikeda K, Morimoto S, Sekigawa I. Aortic Aneurysm as a Complication of Granulomatosis with Polyangiitis Successfully Treated with Prednisolone and Cyclophosphamide: A Case Report and Review of the Literature. Case Rep Rheumatol. :9682801.2018
10. Hayakawa K, Ikeda K, Fujishiro M, Yoshida Y, Hirai T, Tsushima H, Miyashita T, Morimoto S, Suga Y, Takamori K, Ogawa H, Sekigawa I. Connective Tissue Growth Factor Neutralization Aggravates the Psoriasis Skin Lesion: The Analysis of Psoriasis Model Mice and Patients. Ann Dermatol.;30:47-53. 2018
11. Hirai T, Ikeda K, Tsushima H, Fujishiro M, Hayakawa K, Yoshida Y, Morimoto S, Yamaji K, Takasaki Y, Takamori K, Tamura N, Sekigawa I. Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis. Inflamm Regen.;38:1-9. 2018
12. Tsushima H, Morimoto S, Fujishiro M, Yoshida Y, Hayakawa K, Hirai T, Miyashita T, Ikeda K, Yamaji K, Takamori K, Takasaki Y, Sekigawa I, Tamura N. Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis. Autoimmunity.;50:329-335. 2017
13. Sugiura-Ogasawara M, Omae Y, Kawashima M, Toyo-Oka L, Khor SS, Sawai H, Horita T, Atsumi T, Murashima A, Fujita D, Fujita T, Morimoto S, Morishita E, Katsuragi S, Kitaori T, Katano K, Ozaki Y, Tokunaga K. The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome. J Hum Genet.;62:831-838. 2017
14. Miyashita T, Morimoto S, Honda D, Nakano S, Amano H, Osawa I, Yamaji K, Tomino Y, Takasaki Y, Tamura N. Outcomes of the Re-classification of WHO Class IV Lupus Nephritis Using the ISN/RPS Classification: a Single Center Retrospective Observational Study from the JUDE Study. Juntendo Medical Journal.;63:362-369. 2017
15. Minowa K, Amano H, Ando S, Watanabe T, Ogasawara M, Kawano S, Kaneko T, Morimoto S, Yamaji K, Tamura N, Tokano Y, Hashimoto H, Takasaki Y. Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study. Mod Rheumatol.;27:72-76. 2017
16. Ikeda K, Watanabe K, Hirai T, Tanji K, Miyashita T, Nakajima S, Uomori K, Morimoto S, Takamori K, Ogawa H, Takasaki Y, Sekigawa I. Mizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies. Intern Med.;56:1147-1152. 2017
17. Ikeda K, Nakajima S, Tanji K, Hirai T, Uomori K, Morimoto S, Tomita S, Fukunaga M, Tamura N, Sekigawa I. Intestinal perforation due to hemorrhagic Cytomegalovirus enteritis in a patient with severe uncontrolled lupus nephritis: a case and review of the literature. Rheumatol Int. ;37:1395-1399. 2017
18. Ikeda K, Hayakawa K, Fujishiro M, Kawasaki M, Hirai T, Tsushima H, Miyashita T, Suzuki S, Morimoto S, Tamura N, Takamori K, Ogawa H, Sekigawa I. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol.;18:41. 2017
19. Hirai T, Ikeda K, Fujishiro M, Tsushima H, Hayakawa K, Suzuki S, Yamaguchi A, Nozawa K, Morimoto S, Takasaki Y, Ogawa H, Takamori K, Tamura N, Sekigawa I. The effectiveness of new triple combination therapy using synthetic disease-modifying anti-rheumatic drugs with different pharmacological function against rheumatoid arthritis: the verification by an in vitro and clinical study. Clin Rheumatol.; 36:51-8. 2017

研究者

教育活動

【学校法人順天堂】研究者情報データベース

研究業績詳細

森本 真司（モリモト シンジ）

森本真司（モリモトシンジ）